EAACI Congress 2024
BackAllergen immunotherapy 5
Sunday 02 Jun, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
300 IR 5-grass pollen sublingual immunotherapy tablet for allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies
12:00
Analyzing Factors Influencing Adherence to Classify Adherence Levels in Patients Treated with Allergen Immunotherapy
12:00
Efficacy and safety of HDM-specific subcutaneous immunotherapy on atopic dermatitis
12:00
Evaluation of patients’ expectation and benefits of sublingual Named-Patient Products in the treatment of allergic respiratory diseases: the French ERAPP prospective cohort study
12:00
Impact of liquid sublingual immunotherapy on asthma worsening prevention: GINA treatment stepping up results from the real-world EfficAPSI study
12:00
In vitro and ex vivo assessment of the immunogenicity and safety of a depigmented-polymerized extract from Juniperus ashei
12:00
MicroCrystalline Tyrosine and Monophosphoryl Lipid A: an adjuvant system which aids the immunogenic effect of SCIT
12:00
Safety data of subcutaneous inmunotherapy at an allergy inmunotherapy unit in Madrid, Spain
12:00
Short-term benefits of sublingual immunotherapy in routine clinical practice: Patient Benefit Index by class in the observational, prospective, longitudinal study PRACTIS
12:00
Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
12:00
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is safe in a pre/co-seasonal treatment regimen - a subgroup comparison
12:00
Systemic allergic reactions to subcutaneous allergen immunotherapy – A single center experience
12:00
Сytokine profile in patients with allergic rhinitis during allergen-specific immunotherapy with added vitamin D
